NASDAQ / LIVE COMPANY INTELLIGENCE

Zymeworks Inc.

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERZYME
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / ZYME COVERAGE

What’s moving Zymeworks Inc. now

Current reporting with the operating signal separated from the noise.

01
Here's Why Zymeworks Inc. Paid $929 Million For Theravance Biopharma

Here's Why Zymeworks Inc. Paid $929 Million For Theravance Biopharma

The development tests whether Zymeworks Inc. can turn product investment into adoption, revenue and durable advantage.

Watch next: confirmation in a company filing, official release or regulator record.
02
Zymeworks Inc.: Zymeworks to Acquire Theravance Biopharma, Inc.

Zymeworks Inc.: Zymeworks to Acquire Theravance Biopharma, Inc.

The story matters when it changes Zymeworks Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
03
Zymeworks Inc. (ZYME) Q1 2026 Earnings Call Transcript

Zymeworks Inc. (ZYME) Q1 2026 Earnings Call Transcript

Investors are testing whether Zymeworks Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
04
Zymeworks Inc. (ZYME) reports Q1 loss, misses revenue estimates

Zymeworks Inc. (ZYME) reports Q1 loss, misses revenue estimates

Investors are testing whether Zymeworks Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
05
Zymeworks Inc. Presents Promising Preclinical Data on Antibody-Drug Conjugates and T Cell Engagers at AACR Annual Meeting 2025

Zymeworks Inc. Presents Promising Preclinical Data on Antibody-Drug Conjugates and T Cell Engagers at AACR Annual Meeting 2025

The story matters when it changes Zymeworks Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
06
Zymeworks Inc. Appoints Oleg Nodelman to Board of Directors as Part of Ongoing Board Renewal Process

Zymeworks Inc. Appoints Oleg Nodelman to Board of Directors as Part of Ongoing Board Renewal Process

The story matters when it changes Zymeworks Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
PRIMARY DOCUMENTS / SEC EDGAR

Latest ZYME filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

10-QQuarterly financial reportFiled 2026-05-07 · Period 2026-03-31SEC ↗10-QQuarterly financial reportFiled 2025-11-06 · Period 2025-09-30SEC ↗10-KAnnual financial reportFiled 2026-03-02 · Period 2025-12-31SEC ↗8-KMaterial company eventFiled 2026-06-29 · Period 2026-06-28SEC ↗8-KMaterial company eventFiled 2026-05-14 · Period 2026-05-14SEC ↗8-KMaterial company eventFiled 2026-05-07 · Period 2026-05-07SEC ↗DEF 14AProxy and shareholder meetingFiled 2025-11-10 · Period 2025-12-30SEC ↗4Official SEC filingFiled 2026-07-06 · Period 2026-07-06SEC ↗
EARNINGS / QUARTERLY TRACKER

Zymeworks Inc., quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.